A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer
Latest Information Update: 26 Jun 2023
Price :
$35 *
At a glance
- Drugs Dutasteride (Primary)
- Indications Benign prostatic hyperplasia; Prostate cancer
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 21 Mar 2009 Results presented at EAU
- 12 Oct 2008 Trial phase changed from II/III to IV as reported by ClinicalTrials.gov.
- 08 Nov 2007 Status changed from recruiting to completed